Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 7, 2013 - Issue 4
Submit an article Journal homepage
254
Views
12
CrossRef citations to date
0
Altmetric
Review

Advances in and the potential of vaccines for respiratory syncytial virus

Patricia A Jorquera College of Veterinary Medicine, Department of Infectious Disease, Animal Health Research Center, 111 Carlton Street, University of Georgia, Athens, GA 30602, USA. [email protected]
,
Katie E Oakley College of Veterinary Medicine, Department of Infectious Disease, Animal Health Research Center, 111 Carlton Street, University of Georgia, Athens, GA 30602, USA. [email protected]
&
Ralph A Tripp College of Veterinary Medicine, Department of Infectious Disease, Animal Health Research Center, 111 Carlton Street, University of Georgia, Athens, GA 30602, USA. [email protected]
Pages 411-427 | Published online: 09 Jan 2014

References

  • Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282, 1440–1446 (1999).
  • Hall CB, Weinberg GA, Iwane MK et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360, 588–598 (2009).
  • Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179–186 (2003).
  • Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect. Disord. Drug Targets 12, 92–97 (2012).
  • Zeng R, Cui Y, Hai Y, Liu Y. Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines. Virus Res. 167, 138–145 (2012).
  • Ramet M, Korppi M, Hallman M. Pattern recognition receptors and genetic risk for rsv infection: value for clinical decision-making? Pediatr. Pulmonol. 46, 101–110 (2011).
  • Klein Klouwenberg P, Tan L, Werkman W, van Bleek GM, Coenjaerts F. The role of Toll-like receptors in regulating the immune response against respiratory syncytial virus. Crit. Rev. Immunol. 29, 531–550 (2009).
  • Lukacs NW, Smit JJ, Schaller MA, Lindell DM. Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. Viral Immunol. 21, 115–122 (2008).
  • Tripp RA. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 17, 165–181 (2004).
  • Inamori K, Ariki S, Kawabata S. A Toll-like receptor in horseshoe crabs. Immunol.l Rev. 198, 106–115 (2004).
  • Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1, 398–401 (2000).
  • Xie XH, Liu EM, Yang XQ et al. Toll-like receptor 4 expression and function of respiratory syncytial virus-infected airway epithelial cells. Zhonghua Jie He He Hu Xi Za Zhi 31, 213–217 (2008).
  • Monick MM, Yarovinsky TO, Powers LS et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J. Biol. Chem. 278, 53035–53044 (2003).
  • Marr N, Turvey SE. Role of human TLR4 in respiratory syncytial virus-induced NF-kappaB activation, viral entry and replication. Innate Immun. 18, 856–865 (2012).
  • Haeberle HA, Takizawa R, Casola A et al. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J. Infect. Dis. 186, 1199–1206 (2002).
  • Shirey KA, Pletneva LM, Puche AC, et al. Control of RSV-induced lung injury by alternatively activated macrophages is IL-4R alpha-, TLR4-, and IFN-beta-dependent. Mucosal Immunol. 3, 291–300 (2010).
  • Paulus SC, Hirschfeld AF, Victor RE, Brunstein J, Thomas E, Turvey SE. Common human Toll-like receptor 4 polymorphisms – role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin. Immunol. 123, 252–257 (2007).
  • Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75, 10730–10737 (2001).
  • Gagro A, Tominac M, Krsulovic-Hresic V et al. Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. Clin. Exp. Immunol 135, 267–272 (2004).
  • Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25, 187–191 (2000).
  • Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch. Intern. Med. 162, 1028–1032 (2002).
  • Mandelberg A, Tal G, Naugolny L, Cesar K et al. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis. Clin. Exp. Immunol. 144, 48–52 (2006).
  • Tal G, Mandelberg A, Dalal I et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. infect. Dis. 189, 2057–2063 (2004).
  • Smyth RL. Innate immunity in respiratory syncytial virus bronchiolitis. Experimental lung research 33, 543–547 (2007).
  • Zhang W, Lockey RF, Mohapatra SS. Respiratory syncytial virus: immunopathology and control. Expert Rev. Clin. Immunol. 2, 169–179 (2006).
  • Durbin JE, Durbin RK. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol. 17, 370–380 (2004).
  • Krishnan S, Halonen M, Welliver RC. Innate immune responses in respiratory syncytial virus infections. Viral Immunol. 17, 220–233 (2004).
  • Harris J, Werling D. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell. Microbiol. 5, 671–680 (2003).
  • Rosenberg HF, Domachowske JB. Eosinophils, ribonucleases and host defense: solving the puzzle. Immunol. Res. 20, 261–274 (1999).
  • Tripp RA, Oshansky C, Alvarez R. Cytokines and respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2, 147–149 (2005).
  • Oshansky CM, Zhang W, Moore E, Tripp RA. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4, 279–297 (2009).
  • Openshaw PJ. Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2, 121–125 (2005).
  • Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV). F, G, M2 (22K). N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65, 1634–1637 (1991).
  • Schmidt AC, Johnson TR, Openshaw PJ et al. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium – RSV 2003. Virus Res. 106, 1–13 (2004).
  • Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 239, 149–166 (2011).
  • Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63, 2941–2950 (1989).
  • Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, maternal antibody level. J. Pediatr. 98, 708–715 (1981).
  • Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev. Vaccines 10, 1415–1433 (2011).
  • Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82, 2040–2055 (2008).
  • Beem M. Repeated infections with respiratory syncytial virus. J. Immunol. 98, 1115–1122 (1967).
  • Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693–698 (1991).
  • Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543–546 (1986).
  • Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093–1104 (2005).
  • Committee on Infectious, D. From the American Academy of Pediatrics: Policy statements – modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 124, 1694–1701 (2009).
  • Mejias A, Ramilo O. Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2, 433–439 (2008).
  • Malley R, DeVincenzo J, Ramilo O et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178, 1555–1561 (1998).
  • Ottolini MG, Curtis SJ, Porter DD et al. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. 46, 2299–2302 (2002).
  • Prince GA, Mathews A, Curtis SJ, Porter DD. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. 182, 1326–1330 (2000).
  • Anderson LJ, Hierholzer JC, Tsou C et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J. Infect. Dis. 151, 626–633 (1985).
  • Langedijk JP, Schaaper WM, Meloen RH, van Oirschot JT. Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. J. Gen. Virol. 77(Pt 6), 1249–1257 (1996).
  • Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol. 176, 1600–1608 (2006).
  • Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2, 732–738 (2001).
  • Shingai M, Azuma M, Ebihara T et al. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction. Int. Immunol. 20, 1169–1180 (2008).
  • Bukreyev A, Yang L, Fricke J et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82, 12191–12204 (2008).
  • Maher CF, Hussell T, Blair E, Ring CJ, Openshaw PJ. Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 6, 1049–1055 (2004).
  • Zhang W, Choi Y, Haynes LM et al. Vaccination to induce antibodies blocking the CX3C–CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J. Virol. 84, 1148–1157 (2010).
  • Collarini EJ, Lee FE, Foord O et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J. Immunol. 183, 6338–6345 (2009).
  • Mills JT, Van Kirk JE, Wright PF, Chanock RM. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J. Immunol. 107, 123–130 (1971).
  • Spiekermann GM, Finn PW, Ward ES et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 196, 303–310 (2002).
  • Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162, 80–99 (2011).
  • Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N. Engl.J. Med. 315, 77–81 (1986).
  • Cannon MJ, Stott EJ, Taylor G, Askonas BA. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 62, 133–138 (1987).
  • Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Investig. 88, 1026–1033 (1991).
  • Cherrie AH, Anderson K, Wertz GW, Openshaw PJ. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J. Virol. 66, 2102–2110 (1992).
  • Openshaw PJ, Anderson K, Wertz GW, Askonas BA. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J. Virol. 64, 1683–1689 (1990).
  • Taylor G, Stott EJ, Hayle AJ. Cytotoxic lymphocytes in the lungs of mice infected with respiratory syncytial virus. J. Gen. Virol. 66(Pt 12), 2533–2538 (1985).
  • Anderson JJ, Norden J, Saunders D, Toms GL, Scott R. Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection. J. Gen. Virol. 71(Pt 7), 1561–1570 (1990).
  • Bangham CR, Cannon MJ, Karzon DT, Askonas BA. Cytotoxic T-cell response to respiratory syncytial virus in mice. J. Virol. 56, 55–59 (1985).
  • Kumagai T, Wong DT, Ogra PL. Development of cell-mediated cytotoxic activity in the respiratory tract after experimental infection with respiratory syncytial virus. Clin. Exp. Immunol. 61, 351–359 (1985).
  • Kimpen JL, Ogra PL. T cell redistribution kinetics after secondary infection of BALB/c mice with respiratory syncytial virus. Clin. Exp. Immunol. 91, 78–82 (1993).
  • Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J. Immunol. 181, 7958–7968 (2008).
  • Heidema J, Lukens MV, van Maren WW et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J. Immunol. 179, 8410–8417 (2007).
  • Williams MA, Holmes BJ, Sun JC, Bevan MJ. Developing and maintaining protective CD8+ memory T cells. Immunol. Rev. 211, 146–153 (2006).
  • Surman SL, Brown SA, Jones BG, Woodland DL, Hurwitz JL. Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin. AIDS Res. Hum. Retroviruses 26, 783–793 (2010).
  • Plotnicky-Gilquin H, Robert A, Chevalet L et al. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. J. Virol. 74, 3455–3463 (2000).
  • Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7, 145–173 (1989).
  • Kelso A. Th1 and Th2 subsets: paradigms lost? Immunol. Today 16, 374–379 (1995).
  • Lotz MT, Peebles RS Jr. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr. Allergy Asthma Rep. 12, 380–387 (2012).
  • Mukherjee S, Lindell DM, Berlin AA et al. IL-17–induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am. J. Pathol. 179, 248–258 (2011).
  • Fulton RB, Meyerholz DK, Varga SM. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J. Immunol. 185, 2382–2392 (2010).
  • van Schaik SM, Obot N, Enhorning G et al. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J. Med. Virol. 62, 257–266 (2000).
  • Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J. Exp. Med. 168, 1163–1168 (1988).
  • DeVincenzo JP, Wilkinson T, Vaishnaw A et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 182, 1305–1314 (2010).
  • DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J. Infect. Dis. 191, 1861–1868 (2005).
  • Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev. Anti Infect. Ther. 9, 27–32 (2011).
  • Corneli HM, Zorc JJ, Mahajan P et al.; Bronchiolitis Study Group of the Pediatric Emergency Care Applied Research, N. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N. Engl. J. Med. 357, 331–339 (2007).
  • Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2, 655–661 (2010).
  • Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89, 449–463 (1969).
  • Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89, 405–421 (1969).
  • Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435–448 (1969).
  • Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422–434 (1969).
  • Murphy BR, Prince GA, Walsh EE et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Cl. Microbiol. 24, 197–202 (1986).
  • Polack FP, Teng MN, Collins PL et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859–865 (2002).
  • Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151, 2032–2040 (1993).
  • Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization. Vaccine 8, 497–502 (1990).
  • Prince GA, Jenson AB, Hemming VG et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57, 721–728 (1986).
  • Gershwin LJ, Schelegle ES, Gunther RA et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 16, 1225–1236 (1998).
  • de Waal L, Power UF, Yuksel S et al. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22, 915–922 (2004).
  • Tang YW, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J. Clin. Invest. 94, 1953–1958 (1994).
  • Ahlers JD, Belyakov IM, Terabe M et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad. Sci. USA 99, 13020–13025 (2002).
  • Loebbermann J, Durant L, Thornton H, Johansson C, Openshaw PJ. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc. Natl Acad. Sci. USA 110, 2987–2992 (2013).
  • Burl S, Townend J, Njie-Jobe J et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PloS ONE 6, e18185 (2011).
  • Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. Immunol. 7, 379–390 (2007).
  • Willems F, Vollstedt S, Suter M. Phenotype and function of neonatal DC. Eur. J. Immunol. 39, 26–35 (2009).
  • Crowe JE Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin. Infect. Dis. 33, 1720-1727 (2001).
  • Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182, 1331-1342 (2000).
  • Schickli JH, Kaur J, Tang RS. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures. Virus Res. 169, 38–47 (2012).
  • Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21, 3465–3467 (2003).
  • Piedra PA, Grace S, Jewell A et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediat. Infect. Dis. J. 15, 23–31 (1996).
  • Piedra PA, Grace S, Jewell A et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediat. Infect. Dis. J. 17, 217–224 (1998).
  • Piedra PA, Cron SG, Jewell A et al. and Purified Fusion Protein Vaccine Study. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21, 2448–2460 (2003).
  • Durbin AP, Karron RA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin. Infect. Dis. 37, 1668–1677 (2003).
  • Langley JM, Sales V, McGeer A et al. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine 27, 5913–5919 (2009).
  • Power UF, Nguyen TN, Rietveld E et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. The Journal of infectious diseases 184, 1456–1460 (2001).
  • Nguyen TN, Power UF, Robert A et al. The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents. PloS One 7, e34331 (2012).
  • Glenn GM, Smith G, Fries L et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31, 524–532 (2013).
  • Tang RS, Spaete RR, Thompson MW et al. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26, 6373–6382 (2008).
  • Tang RS, Malkin E, Stillman E et al. Implication of genetic changes observed in Phase 1 evaluation of MEDI-534, a live attenuated chimeric bovine human parainfluenza type 3 vectored RSV vaccine. International RSV symposium 2012 Santa Fe, New Mexico, Poster#38 (2012).
  • Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Investigators, M.-C. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediat. Infect. Dis. J. 31, 109–114 (2012).
  • Shafique M, Wilschut J, de Haan A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 30, 597–606 (2012).
  • Lindell DM, Morris SB, White MP et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PloS One 6, e21823 (2011).
  • Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 24, 5027–5035 (2006).
  • Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum. Vaccines 6, 482–492 (2010).
  • Luongo C, Winter CC, Collins PL, Buchholz UJ. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J. Virol. 86, 10792–10804 (2012).
  • Widjojoatmodjo, MN, Boes, J, van Bers, M, van Remmerden, Y, Roholl, PJ, Luytjes, WA highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virology J. 7, 114 (2010).
  • Garlapati S, Garg R, Brownlie R et al. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 30, 5206–5214 (2012).
  • Cherukuri A, Stokes KL, Patton K et al. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun. Ageing 9, 21 (2012).
  • Murata Y, Catherman SC. Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice. Vaccine 30, 5382–5388 (2012).
  • Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 25, 193–203 (2012).
  • Murata Y, Lightfoote PM, Biear JN, Falsey AR, Walsh EE. Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine 28, 6242–6246 (2010).
  • Murata, Y, Lightfoote, PM, Falsey, AR, Walsh, EE. Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein. Clin. Vaccine Immunol. 17, 695–697 (2010).
  • Prince, GA, Capiau, C, Deschamps, M et al.. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J. Virol. 74, 10287–10292 (2000).
  • Remot A, Roux X, Dubuquoy C et al. Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine. PloS ONE 7, e37722 (2012).
  • Powell TJ, Palath N, DeRome ME, Tang J, Jacobs A, Boyd JG. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo. Vaccine 29, 558–569 (2011).
  • Powell TBJ, Jacobs A, Palath N et al. Synthetic LbL nanoparticle vaccines containing the chemokine mimic epitope of RSV-G protein and a CD8 epitope of RSV-M2 protein elicit broad-based cellular and humoral responses. J. Immunol. 186, (Meeting Abstract Supplement) (2011).
  • Quan FS, Kim Y, Lee S et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J. Infect. Dis. 204, 987–995 (2011).
  • Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PloS ONE 7, e36812 (2012).
  • Kamphuis T, Stegmann T, Meijerhof T, Wilschut J, de Haan A. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats. Influenza Other Respi. Viruses (2013).
  • Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. Vaccine 31, 2169–2176 (2013).
  • Yu JR, Kim S, Lee JB, Chang J. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol. 82, 2350–2357 (2008).
  • Fu Y, He J, Zheng X et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem. Biophys. Res Commun. 381, 528–532 (2009).
  • Kohlmann R, Schwannecke S, Tippler B et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J. Virol. 83, 12601–12610 (2009).
  • Fu YH, He JS, Zheng XX et al. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Biochem. Biophys. Res. Commun. 391, 857–861 (2010).
  • Kim S, Jang JE, Yu JR, Chang J. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. Vaccine 28, 3801–3808 (2010).
  • Krause A, Xu Y, Ross S, Wu W, Joh J, Worgall S. Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. Virol. J. 8, 375 (2011).
  • Elliott MB, Chen T, Terio NB et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 25, 7132–7144 (2007).
  • Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J.Immunol. 169, 3208–3216 (2002).
  • Fleeton MN, Chen M, Berglund P et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, a tickborne encephalitis virus. J. Infect. Dis. 183, 1395–1398 (2001).
  • Mok H, Lee S, Utley TJ et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J. Virol. 81, 13710–13722 (2007).
  • Kim S, Chang J. Baculovirus-based vaccine displaying respiratory syncytial virus glycoprotein induces protective immunity against RSV infection without vaccine-enhanced disease. Immune Netw. 12, 8–17 (2012).
  • McGinnes LW, Gravel KA, Finberg RW et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J. Virol. 85, 366–377 (2011).
  • Schmidt MR, McGinnes LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J. Virol. 86, 11654–11662 (2012).
  • Mok H, Cheng X, Xu Q et al. Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein–Barr virus glycoprotein GP350. Open Virol. J. 6, 12–22 (2012).
  • Hurwitz JL, Soike KF, Sangster MY, Portner A, Sealy RE, Dawson DH, Coleclough C. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 15, 533–540 (1997).
  • Slobod KS, Shenep JL, Lujan-Zilbermann J et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22, 3182–3186 (2004).
  • Bousse T, Chambers RL, Scroggs RA, Portner A, Takimoto T. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res. 121, 23–32 (2006).
  • Jones BG, Sealy RE, Rudraraju R et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30, 959–968 (2012).
  • Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalergis AM. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette–Guerin promotes virus clearance and protects from infection. J. Immunol. 185, 7633–7645 (2010).
  • Bueno SM, Gonzalez PA, Cautivo KM et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc. Natl Acad. Sci. USA 105, 20822–20827 (2008).
  • Cano F, Plotnicky-Gilquin H, Nguyen TN et al. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18, 2743–2752 (2000).
  • Vogel FR, Sarver N. Nucleic acid vaccines. Clin. Microbiol. Rev. 8, 406–410 (1995).
  • Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19, 1038–1046 (2000).
  • Li X, Sambhara S, Li C et al. Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188, 681–688 (1998).
  • Bartholdy C, Olszewska W, Stryhn A, Thomsen AR, Openshaw PJ. Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. J. Gen. Virol. 85, 3017–3026 (2004).
  • Geall AJ, Verma A, Otten GR et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. of the Natl Acad. Sci. USA 109, 14604–14609 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.